Company Overview and News

1
BioTime, Inc. (BTX) CEO Aditya Mohanty on Q2 2018 Results - Earnings Call Transcript

2018-08-03 seekingalpha - 1
Good day, ladies and gentlemen, and welcome to the BioTime's Second Quarter 2018 Earnings Conference Call. [Operator Instructions]. And as a reminder, today's conference is being recorded. I would now like to turn the call over to Mr. David Nakasone. Sir, you may begin.
WEB BTX DTK MFX

0
BioTime (BTX) Reports Q2 Loss, Tops Revenue Estimates

2018-08-02 zacks
BioTime (BTX - Free Report) just came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.
SHAK BTX

0
BTX / BioTime, Inc. BIOTIME, INC. 8-K (Current Report)

2018-08-02 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
BTX

1
BioTime (BTX) in Focus: Stock Moves 7.3% Higher

2018-07-12 zacks - 1
BioTime, Inc. (BTX - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $2.03 –$2.38 in the past one-month time frame, witnessed a sharp increase yesterday.
BTX ILMN

76
Asterias Biotherapeutics: A Game Changer For Cervical Spinal Cord Injuries And Cancer

2018-06-22 seekingalpha - 3
Asterias Biotherapeutics is a micro-cap biotechnology company that is focused on cell-based therapies for spinal cord injuries and broad cancer.
AST GERN BTX CCE MS

73
Sangamo Therapeutics: Investability Outlook

2018-06-13 seekingalpha - 5
Like BioTime (BTX), which we discussed recently, Sangamo (SGMO) is another company that began the wrong way, with a platform, and then, and only recently, moved on to therapeutics. But, oh boy, what a move it has been! The company changed its name from Sangamo Biosciences to Sangamo Therapeutics to emphasize that change in direction after its new CEO Sandy Macrae took over, and within about 24 months, changed from a sleepy lab-oriented laggard to a company with multiple deals and pipeline assets.
CLXT SHPG SGMO BTX SIAL PFE BIVV

183
Your Daily Pharma Scoop: Secondaries Review June 4-11

2018-06-12 seekingalpha - 14
Using a set of 3 criterion, we have singled out MEI Pharma's offering for an analysis.
ZYME OPTN DCPH MDGL KSHB BTX TROV CATB VKTX COOL BICX MEIP EXAS VKTXW TPIV PAVM MRTX BCLI ADMA

11
BioTime's (BTX) CEO Adi Mohanty on Q1 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha - 4
Good day, ladies and gentlemen, and welcome to the BioTime's First Quarter Results Conference Call. As a reminder, this conference call is being recorded.
UBX BTX

8
BTX / BioTime, Inc. BIOTIME, INC. 8-K (Current Report)

2018-05-10 sec.gov - 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
BTX

10
BioTime (BTX): Moving Average Crossover Alert

2018-04-10 zacks
BioTime, Inc. (BTX - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for BTX broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.
UNP BTX HEAR

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 09066L105